Pfizer appoints neuroscience research head

pharmafile | June 10, 2010 | Appointment | Research and Development |ย ย Pfizer, appointment, research and developmentย 

Pfizer has appointed Dr Michael Ehlers chief scientific officer for neuroscience research.

Dr Ehlers most recently served as the George Barth Geller Professor in the Department of Neurobiology at Duke University and as an investigator with the Howard Hughes Medical Institute

Prior to this he served as the director of the neuroproteomics laboratory at Duke University.

Advertisement

He has authored over 60 scientific papers, and has been the recipient of numerous scientific awards, including the NARSAD Distinguished Investigator Award in 2009.

In his new role Dr Ehlers will report to Rod MacKenzie, senior vice president and head of PharmaTherapeutics Research & Development.

Dr MacKenzie said: โ€œMike is a world class scientist whose deep understanding of neurobiology will be a powerful asset as we build on the progress in our Neuroscience

Research Unit and apply new thinking to deliver novel therapeutics in Alzheimerโ€™s disease, stroke, autism, and schizophrenia.

โ€œHis experience in the field and his passion for transforming medical outcomes are a winning combination in helping Pfizer create the industryโ€™s leading pipeline of neuroscience medicines.โ€

Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Dรผsseldorf with …

NICE recommends Pfizerโ€™s new once-weekly treatment for haemophilia B on NHS

Walton Oaks, 21stย May 2025ย โ€“ย Pfizer Ltd announced today that the National Institute for Health and Care …

AAX Biotech announces collaboration for cardiovascular antibody therapy

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

The Gateway to Local Adoption Series

Latest content